• home
  • contact
  • join us
About Us
  • Mission
  • Who we are
  • Management
  • Board of Directors
  • Scientific Advisory Board
  • Corporate Achievements

We are a product-focused molecular imaging company with broad expertise and IP in the field of brain imaging.

CORPORATE ACHIEVEMENTS SINCE 2006

  • In-licensed and advanced molecular imaging development programs in three areas: Alzheimer's disease, Parkinson's disease and diabetes
  • Completed license-option agreement with Bayer Schering Pharma for PET amyloid imaging compound.
  • Secured collaborations with four pharmaceutical partners, including several top tier global pharma companies.
  • Raised $9M in Series A/B financing
  • Assembled world class development team and established a state-of-the-art R&D lab.
  • Developed robust pipeline of clinical development compounds from technology in-licensed from the University of Pennsylvania and the University of Michigan.
  • Raised $26M Series C financing.
  • Selected and advanced development compounds into Phase III clinical trials for imaging β-amyloid in Alzheimer's disease and VMAT2 in Phase II for Parkinson's disease, dementia with Lewy bodies, as well as early stage clinical studies in diabetes.
  • Established strong IP position in support of pipeline programs.
  • Raised $34.5M in series D funding and hired Commercialization leader.